Compare Moderna, Inc. (MRNA) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Skyworks Solutions Inc — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while Skyworks Solutions Inc trades at $76.35 (market cap $12.15B). The key difference: Moderna, Inc. is far larger — about 6.5× Skyworks Solutions Inc's market cap, and Skyworks Solutions Inc pays a 4.13% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Skyworks Solutions Inc for 50 Days on average.
| MRNA | SWKS | |
|---|---|---|
Market Cap | $78.65B | $12.15B |
Volume | 37,373,437 | 7,390,810 |
Sector | Health | Technology |
52-Week High | $225.00 | $91.45 |
52-Week Low | $22.36 | $52.50 |
Typical Hold Time | 59 Days | 50 Days |
Enterprise Value | $74.80B | $12.03B |
Dividend Yield | — | 4.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 0.26% today, reflecting a strong 2026 rally. The stock is technically bullish, with moving averages signaling strength and key support at $194. Fundamentally, revenue has declined from pandemic peaks to $1.92 billion in 2025, with net losses widening to -$2.82 billion, though recent quarters have beaten EPS estimates. The company's inclusion in the Nasdaq-100 index effective October 9, 2026, adds a positive catalyst. Analyst sentiment is mixed, with a consensus price target of $115.70 but a high target of $245.00, indicating divergent views on valuation after the stock's significant run-up.
The outlook for Moderna hinges on its pipeline beyond COVID-19, particularly cancer vaccines, but high valuation ratios (P/S of 35.08) and persistent losses pose risks. Upside potential exists if new products gain traction, yet investors face volatility from clinical trial outcomes and competitive pressures. The stock's proximity to 52-week highs suggests caution amid profit-taking signals from some analysts.
Skyworks Solutions (SWKS) trades at $80.75, down 3.21% today, with a bearish technical signal despite recent earnings beats. The company shows declining revenue and profit margins but maintains positive cash flow from operations. The pending Qorvo merger represents a significant strategic move, with regulatory clearances obtained and expected $500M in synergies. Valuation metrics include a P/E of 41.84 and P/S of 3.03, while analyst consensus leans bullish with 60% buy ratings.
The investment outlook balances merger synergies against fundamental deterioration. Near-term catalysts include the Qorvo deal closure and potential market share gains, but risks include integration challenges and ongoing margin pressure. The stock trades near analyst consensus targets, suggesting limited upside from current levels without operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
